CytomX/$CTMX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
120
ISIN
US23284F1057
Website
CytomX Metrics
BasicAdvanced
$373M
4.88
$0.49
1.11
-
Price and volume
Market cap
$373M
Beta
1.11
52-week high
$3.10
52-week low
$0.40
Average daily volume
2.8M
Financial strength
Current ratio
1.726
Quick ratio
1.63
Long term debt to equity
11.402
Total debt to equity
32.532
Profitability
EBITDA (TTM)
37.645
Gross margin (TTM)
100.00%
Net profit margin (TTM)
28.19%
Operating margin (TTM)
24.37%
Effective tax rate (TTM)
0.57%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
15.87%
Return on equity (TTM)
-1,254.80%
Valuation
Price to earnings (TTM)
4.883
Price to revenue (TTM)
1.377
Price to book
7.63
Price to tangible book (TTM)
8.11
Price to free cash flow (TTM)
-2.491
Free cash flow yield (TTM)
-40.14%
Free cash flow per share (TTM)
-95.14%
Growth
Revenue change (TTM)
23.81%
Earnings per share change (TTM)
128.27%
3-year revenue growth (CAGR)
69.35%
10-year revenue growth (CAGR)
37.33%
3-year earnings per share growth (CAGR)
-37.91%
10-year earnings per share growth (CAGR)
-32.49%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Bulls say / Bears say
CytomX reported a 36% increase in revenue for 2024, reaching $138.1 million, primarily driven by progress in collaborations with Bristol Myers Squibb, Moderna, Astellas, and Regeneron. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
The company achieved a $5 million milestone payment from Astellas in February 2025, indicating successful advancement in their collaborative T-cell engager program. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
CytomX's lead program, CX-2051, is progressing in Phase 1 trials for advanced colorectal cancer, with initial data expected in the first half of 2025, potentially opening new treatment avenues. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
In January 2025, CytomX announced a 40% reduction in workforce to focus resources on CX-2051, which may indicate financial constraints and could impact other pipeline developments. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
The discontinuation of the CX-904 program, a collaboration with Amgen, due to clinical observations and pipeline priorities, raises concerns about the viability of certain pipeline assets. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
Despite increased revenue, operating expenses rose to $113.1 million in 2024 from $107.7 million in 2023, primarily due to milestone payments, which could pressure profitability. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
CytomX News
AllArticlesVideos
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
GlobeNewsWire·2 months ago
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $373M as of July 08, 2025.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 4.88 as of July 08, 2025.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.